Skip to content

A Comparison of the Efficacy of Novel G-Protein Biased µ-Opioid Receptor Agonists and Traditional Opioids in Chronic Postoperative Pain Following Thoracoscopic Surgery

A Comparison of the Efficacy of Novel G-Protein Biased µ-Opioid Receptor Agonists and Traditional Opioids in Chronic Postoperative Pain Following Thoracoscopic Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115661
Enrollment
Unknown
Registered
2025-12-29
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic post-surgical pain,CPSP

Interventions

Teglitide Group:A bolus dose of 0.75 mg tegileridine is diluted to 3 ml, and the postoperative IV-PCA pump is prepared with tegileridine at 0.075 mg/kg diluted to a total volume of 200 ml, with a PCA
Oliceridine Group :A bolus dose of 1.5 mg oliceridine is diluted to 3 ml, and the postoperative IV-PCA pump is prepared with oliceridine at 0.15 mg/kg diluted to a total volume of 200 ml, with a PCA b
Sufentanil Group :A bolus dose of 7.5 µg sufentanil is diluted to 3 ml, and the postoperative IV-PCA pump is prepared with sufentanil at 0.75 µg/kg diluted to a total volume of 200 ml, with a PCA bolu

Sponsors

Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients aged between 18 and 80 years, ASA anesthesia classification I-III; 2. Patients undergoing elective thoracoscopic surgery under general anesthesia; 3. Body Mass Index (BMI): 18 kg/m^2 - 28 kg/m^2; 4. Participants fully understand the purpose, content, procedures, and risks of this trial, voluntarily participate in the clinical trial, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Body Mass Index (BMI) 28 kg/m^2; 2. Preoperative moderate to severe liver or kidney dysfunction, or heart failure; 3. Allergy to any of the study drugs; 4. History of analgesic drug abuse; 5. Severe dementia or communication disorders; 6. Patient or family refusal to participate in this study.

Design outcomes

Primary

MeasureTime frame
chronic post-surgical pain;

Secondary

MeasureTime frame
Numeric Rating Scale;Incidence of moderate to severe pain;Opioid-Related Adverse Reactions;Quality of Recovery-15, Qor-15;Neuropathic pain three months after surgery;Anxiety situation three months after surgery;

Countries

China

Contacts

Public ContactCongjie Bi

Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)

bcj0411@126.com+86 135 0425 1513

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026